blenrep
glaxosmithkline (ireland) limited - belantamab mafodotin - mergæxli - Æxlishemjandi lyf - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
jemperli
glaxosmithkline (ireland) limited - dostarlimab - endometrial neoplasms - antineoplastic agents and antibody drug conjugates - jemparli is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dmmr)/microsatellite instability-high (msi h) recurrent or advanced endometrial cancer (ec) that has progressed on or following prior treatment with a platinum-containing regimen.
xevudy
glaxosmithkline trading services limited - sotrovimab - covid-19 virus infection - Ónæmiskerfið sera og mótefni, - xevudy is indicated for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (covid-19) who do not require oxygen supplementation and who are at increased risk of progressing to severe covid-19.
lamictal tuggu-/dreifitafla 50 mg
glaxosmithkline pharma a/s - lamotriginum inn - tuggu-/dreifitafla - 50 mg
lamictal tuggu-/dreifitafla 5 mg
glaxosmithkline pharma a/s - lamotriginum inn - tuggu-/dreifitafla - 5 mg
lamictal tuggu-/dreifitafla 25 mg
glaxosmithkline pharma a/s - lamotriginum inn - tuggu-/dreifitafla - 25 mg
lamictal tuggu-/dreifitafla 200 mg
glaxosmithkline pharma a/s - lamotriginum inn - tuggu-/dreifitafla - 200 mg
lamictal tuggu-/dreifitafla 2 mg
glaxosmithkline pharma a/s - lamotriginum inn - tuggu-/dreifitafla - 2 mg
lamictal tuggu-/dreifitafla 100 mg
glaxosmithkline pharma a/s - lamotriginum inn - tuggu-/dreifitafla - 100 mg
serevent innúðalyf, dreifa 25 míkróg/skammt
glaxosmithkline pharma a/s - salmeterolum xínafóat - innúðalyf, dreifa - 25 míkróg/skammt